Source hierarchy
We prioritize health authorities, regulators, official transplant programmes, recognized professional bodies, peer-reviewed literature, and direct institutional sources. Marketing claims and unsourced comparisons are not treated as evidence.
Clinical review
Phase 1 introductory content is clearly marked as awaiting independent clinical approval. Before expansion into detailed clinical guidance, named qualified reviewers and a documented sign-off process must be approved.
Corrections and review dates
Published records include dates and source panels. Material errors should be corrected promptly, with affected pages reviewed for related inaccuracies. Country and hospital claims will require scheduled re-verification before publication.
Independence and disclosure
Editorial conclusions must remain independent of referral, partnership, or commercial arrangements. Any relevant relationship will be clearly disclosed near the affected content.
What we will not publish
We will not publish unverified success rates, rankings, cost promises, access guarantees, donor availability, waiting-time claims, or content that could facilitate unlawful transplantation.